OREANDA-NEWS. On 16 June 2009 JSC "Grindeks" informed on business analysis regarding manufacturing expansion and establishment of injection plant. The purchase of the injections manufacturing company is another option for expansion that is still on the agenda. Any decisions regarding establishment or purchase of the injection plant are not taken yet. At the moment injections are produced under the contract manufacturing agreements in pharmaceutical companies in Lithuania, Poland and Slovakia.

"Grindeks" believes that it will keep the current growth dynamics in existing and new markets and finish the year 2009 successfully with up to 78 million lats turnover. 

"Grindeks" works actively to complete the registration process of the brand product Mildronate® in China until the end of 2009. The positive result will depend on decisions of China State Food and Drug Administration agency whether to carry out additional research of Mildronate® technology.